---
title: "12 Health Care Stocks Moving In Tuesday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305010932.md"
description: "In Tuesday's pre-market session, healthcare stocks showed mixed movements. Gainers included Co-Diagnostics (+22.4%), Burning Rock Biotech (+19.45%), and Skye Bioscience (+16.42%). Losers featured Karyopharm Therapeutics (-18.8%), Bluejay Diagnostics (-12.86%), and GeneDx Holdings (-11.75%). Several companies reported Q3 earnings, influencing their stock performance."
datetime: "2026-11-10T12:05:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305010932.md)
  - [en](https://longbridge.com/en/news/305010932.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305010932.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

### Gainers

-   **Co-Diagnostics** (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out today.
-   **Burning Rock Biotech** (NASDAQ:BNR) stock moved upwards by 19.45% to $14.8. The market value of their outstanding shares is at $130.6 million.
-   **Skye Bioscience** (NASDAQ:SKYE) shares moved upwards by 16.42% to $0.8. The market value of their outstanding shares is at $3.0 million.
-   **Eikon Therapeutics** (NASDAQ:EIKN) shares moved upwards by 15.84% to $6.8. The market value of their outstanding shares is at $317.9 million.
-   **Harrow** (NASDAQ:HROW) stock rose 15.61% to $31.76. The company's market cap stands at $1.0 billion. As per the press release, Q3 earnings came out yesterday.
-   **Senseonics Holdings** (NASDAQ:SENS) stock increased by 13.26% to $11.1. The market value of their outstanding shares is at $518.1 million. As per the news, the Q3 earnings report came out yesterday.

### Losers

-   **Karyopharm Therapeutics** (NASDAQ:KPTI) stock decreased by 18.8% to $0.03 during Tuesday's pre-market session.
-   **Bluejay Diagnostics** (NASDAQ:BJDX) shares declined by 12.86% to $2.17. The company's market cap stands at $2.7 million.
-   **GeneDx Holdings** (NASDAQ:WGS) shares fell 11.75% to $58.0. The company's market cap stands at $1.9 billion. As per the news, the Q3 earnings report came out yesterday.
-   **Nordicus Partners** (NASDAQ:NORD) stock fell 11.65% to $3.11. The company's market cap stands at $68.4 million.
-   **Lakewood-Amedex** (NASDAQ:LABT) stock decreased by 10.96% to $0.37.
-   **Jade Biosciences** (NASDAQ:JBIO) stock declined by 9.62% to $14.1. The company's market cap stands at $992.1 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [BJDX.US](https://longbridge.com/en/quote/BJDX.US.md)
- [BNR.US](https://longbridge.com/en/quote/BNR.US.md)
- [CODX.US](https://longbridge.com/en/quote/CODX.US.md)
- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)
- [SKYE.US](https://longbridge.com/en/quote/SKYE.US.md)
- [WGS.US](https://longbridge.com/en/quote/WGS.US.md)
- [KPTIQ.US](https://longbridge.com/en/quote/KPTIQ.US.md)
- [EIKN.US](https://longbridge.com/en/quote/EIKN.US.md)
- [HROW.US](https://longbridge.com/en/quote/HROW.US.md)
- [JBIO.US](https://longbridge.com/en/quote/JBIO.US.md)
- [LABT.US](https://longbridge.com/en/quote/LABT.US.md)
- [NORD.US](https://longbridge.com/en/quote/NORD.US.md)
- [SENS.US](https://longbridge.com/en/quote/SENS.US.md)

## Related News & Research

- [Why GeneDx Holdings stock just dropped 16.6%](https://longbridge.com/en/news/305080597.md)
- [BNR: €47 million of Q3 savings support the €150 million FY target amid margin and cost pressures](https://longbridge.com/en/news/305186335.md)
- [GeneDx Study Finds 62% of Patients With Pathogenic or Likely Pathogenic Findings Have Medically Actionable Results](https://longbridge.com/en/news/305020625.md)
- [Co-Diagnostics Q3 revenue rises, operating expenses fall 12%](https://longbridge.com/en/news/305019639.md)
- [WGS: Q3 growth in genomic testing was offset by widening losses, impairment and looming reimbursement cuts](https://longbridge.com/en/news/304910386.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**